Contact us today

Revio Therapeutics specializes in uncovering new possibilities for approved drugs, specifically for rare diseases and niche indications. This approach accelerates drug development, reduces risks, and improves patient outcomes.

Rare diseases often have significant unmet needs, with over 95% lacking FDA-approved treatments. Revio focuses on these areas to maximize impact, leveraging regulatory and commercial incentives that minimize risks in drug development.

Revio uses AI-driven approaches to identify new applications for approved drugs. For example, its muscular dystrophy program uses AI to uncover the therapeutic potential of a small molecule, which is now progressing to clinical trials.

Revio partners with academic researchers and biotech firms for early-stage ideas and collaborates with pharmaceutical companies for late-stage development and commercialization. Revio values mutually beneficial partnerships that drive innovation and success.

If you are an academic researcher, a biotech or pharmaceutical company with ideas or assets for repurposing approved drugs, Revio would love to hear from you. You can reach out through the contact form on this website to discuss partnership opportunities.